Efficacy, Safety, and Pharmacokinetics of QAW039

ClinicalTrials.gov ID: NCT01253603

Public ClinicalTrials.gov record NCT01253603. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Pharmacokinetics of QAW039 in Steroid-free Patients With Mild to Moderate Persistent Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the safety, efficacy and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma.

Study identification

NCT ID: NCT01253603
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 170 participants

Conditions and interventions

Conditions

Persistent Asthma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2010 (Type not available)
Primary completion: Sep 2011 (Actual)
Completion: Sep 2011 (Actual)
Last update posted: Dec 19, 2020

2010 – 2011

United States locations

U.S. sites: 18
U.S. states: 9
U.S. cities: 16

Facility	City	State	ZIP	Site status
Novartis Investigative Site	Encinitas	California	92024	—
Novartis Investigative Site	Huntington Beach	California	92647	—
Novartis Investigative Site	Los Angeles	California	90025	—
Novartis Investigative Site	Los Angeles	California	90048	—
Novartis Investigative Site	Mission Viejo	California	92691	—
Novartis Investigative Site	San Diego	California	92120	—
Novartis Investigative Site	San Diego	California	92123	—
Novartis Investigative Site	San Jose	California	95117	—
Novartis Investigative Site	Stockton	California	95207	—
Novartis Investigative Site	Stockbridge	Georgia	30281	—
Novartis Investigative Site	North Dartmouth	Massachusetts	02747	—
Novartis Investigative Site	Bellevue	Nebraska	68123	—
Novartis Investigative Site	Berlin	New Jersey	08009	—
Novartis Investigative Site	Skillman	New Jersey	08558	—
Novartis Investigative Site	Raleigh	North Carolina	27607	—
Novartis Investigative Site	Medford	Oregon	97504	—
Novatis Investigative Site	Upland	Pennsylvania	19013	—
Novartis Investigative Site	Dallas	Texas	75231	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01253603, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 19, 2020 · Synced Oct 18, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01253603 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →